Klemm P, Warner T D, Hohlfeld T, Corder R, Vane J R
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, United Kingdom.
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2691-5. doi: 10.1073/pnas.92.7.2691.
Treatment of rats with cytokines has been associated with an increase in the circulating levels of endothelin 1 (ET-1). Here we show that administration of tumor necrosis factor alpha (TNF-alpha; 4 micrograms.kg-1) to anesthetized rats caused within 15 min a strong elevation in the circulating levels of ET-1. This was associated with a striking coronary vasoconstriction in hearts from these animals when they were removed and perfused in vitro by the Langendorff technique. This vasoconstriction was largely overcome by treatment with either the endothelin type A (ETA) receptor antagonist FR 139317 or antibody against ET-1. Furthermore, it was mimicked by in vivo exposure to exogenous ET-1. Endogenously produced TNF-alpha may also cause such a coronary vasoconstriction, for treatment with interleukin 2 (600 micrograms.kg-1) produced an increase in coronary perfusion pressure that correlated with the increases in circulating TNF-alpha. This coronary vasoconstriction was substantially reversed by treatment either with antibody against TNF-alpha or with FR 139317. We suggest, therefore, that cytokine-driven changes in the production of ET-1 are key events in the development of vascular pathologies.
用细胞因子处理大鼠与内皮素1(ET-1)循环水平升高有关。在此我们表明,给麻醉大鼠注射肿瘤坏死因子α(TNF-α;4微克·千克⁻¹)在15分钟内导致ET-1循环水平大幅升高。当这些动物的心脏被取出并通过Langendorff技术进行体外灌注时,这与显著的冠状动脉血管收缩有关。用内皮素A型(ETA)受体拮抗剂FR 139317或抗ET-1抗体处理可在很大程度上克服这种血管收缩。此外,体内暴露于外源性ET-1可模拟这种情况。内源性产生的TNF-α也可能导致这种冠状动脉血管收缩,因为用白细胞介素2(600微克·千克⁻¹)处理会使冠状动脉灌注压升高,这与循环TNF-α的增加相关。用抗TNF-α抗体或FR 139317处理可使这种冠状动脉血管收缩得到显著逆转。因此,我们认为细胞因子驱动的ET-1产生变化是血管病变发展中的关键事件。